Cary Street Partners Financial LLC Acquires Shares of 19,168 Haleon plc (NYSE:HLN)

Cary Street Partners Financial LLC bought a new stake in shares of Haleon plc (NYSE:HLN) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 19,168 shares of the company’s stock, valued at approximately $183,000.

Other institutional investors also recently modified their holdings of the company. Procyon Advisors LLC raised its holdings in shares of Haleon by 41.3% during the fourth quarter. Procyon Advisors LLC now owns 230,240 shares of the company’s stock worth $2,196,000 after acquiring an additional 67,329 shares in the last quarter. Bank of New York Mellon Corp raised its stake in shares of Haleon by 29.8% during the 4th quarter. Bank of New York Mellon Corp now owns 2,071,017 shares of the company’s stock worth $19,758,000 after purchasing an additional 475,934 shares in the last quarter. SeaCrest Wealth Management LLC acquired a new stake in shares of Haleon during the 4th quarter valued at about $102,000. Atria Wealth Solutions Inc. grew its stake in shares of Haleon by 6.1% in the 4th quarter. Atria Wealth Solutions Inc. now owns 47,868 shares of the company’s stock valued at $457,000 after buying an additional 2,758 shares in the last quarter. Finally, Janney Montgomery Scott LLC grew its stake in shares of Haleon by 13.3% in the 4th quarter. Janney Montgomery Scott LLC now owns 850,563 shares of the company’s stock valued at $8,114,000 after buying an additional 99,666 shares in the last quarter. Institutional investors and hedge funds own 6.67% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Morgan Stanley raised shares of Haleon from an “equal weight” rating to an “overweight” rating and set a $11.25 price objective on the stock in a research report on Friday. Hsbc Global Res lowered shares of Haleon from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, March 5th. Barclays reaffirmed an “overweight” rating on shares of Haleon in a research note on Tuesday, May 6th. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Haleon in a report on Monday, March 3rd. Finally, HSBC reiterated a “hold” rating on shares of Haleon in a research note on Wednesday, March 5th. Five investment analysts have rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $11.25.

Haleon Price Performance

Shares of NYSE:HLN opened at $10.75 on Monday. The business’s 50 day moving average is $10.20 and its 200-day moving average is $9.84. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44. The firm has a market capitalization of $48.48 billion, a PE ratio of 31.62, a PEG ratio of 2.82 and a beta of 0.24. Haleon plc has a 1-year low of $8.24 and a 1-year high of $10.85.

Haleon (NYSE:HLN) last announced its earnings results on Thursday, February 27th. The company reported $0.05 EPS for the quarter. Haleon had a return on equity of 14.76% and a net margin of 10.85%. The business had revenue of $3.54 billion for the quarter, compared to the consensus estimate of $3.38 billion. Sell-side analysts predict that Haleon plc will post 0.43 earnings per share for the current year.

Haleon Increases Dividend

The firm also recently announced a — dividend, which will be paid on Thursday, June 5th. Stockholders of record on Friday, April 25th will be issued a dividend of $0.1166 per share. This represents a dividend yield of 1.6%. The ex-dividend date is Friday, April 25th. This is a boost from Haleon’s previous — dividend of $0.05. Haleon’s dividend payout ratio is presently 58.97%.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.